Scarica l'app Stockscreener
46.90
1.61%
0.75
Precedente Chiudi:
$46.15
Aprire:
$47
Volume 24 ore:
402.30K
Relative Volume:
0.34
Capitalizzazione di mercato:
$3.74B
Reddito:
$541.74M
Utile/perdita netta:
$88.01M
Rapporto P/E:
43.18
EPS:
1.0862
Flusso di cassa netto:
$155.34M
1 W Prestazione:
+1.23%
1M Prestazione:
-16.50%
6M Prestazione:
+29.57%
1 anno Prestazione:
+69.40%
Intervallo 1D:
$46.21
$47.80
Intervallo di 1 settimana:
$43.09
$47.96
Portata 52W:
$26.61
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
46.88 | 4.44B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
587.13 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.72 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
587.76 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
317.63 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
145.09 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Jefferies | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Underweight |
| 2025-10-20 | Iniziato | Canaccord Genuity | Hold |
| 2025-03-20 | Iniziato | Craig Hallum | Buy |
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
VCYT|Veracyte Inc|Price:55.615|Chg%:-0.995 - TradingKey
Veracyte Inc (VCYT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VCYT|Veracyte Inc|Price:56.610|Chg%:-1.270 - TradingKey
TradingKey - TradingKey
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veracyte Inc (VCYT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance - ChartMill
ETFs Investing in Veracyte, Inc. Stocks - TradingView
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline - Yahoo Finance
Brittan McClanahan Starts a New Leadership Role at Veracyte - Oncodaily
Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now - MSN
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51 - GuruFocus
Piper Sandler Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $66 - Moomoo
Piper Sandler initiates Veracyte stock with overweight rating - Investing.com UK
Piper Sandler initiates Veracyte stock with overweight rating By Investing.com - Investing.com South Africa
Piper Sandler Initiates Veracyte at Overweight With $66 Price Target - marketscreener.com
VCYT Initiated Coverage by Piper Sandler -- Rating Overweight - GuruFocus
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60 - Moomoo
Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN
Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47 - Moomoo
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - BioSpace
A Look at Veracyte Inc (VCYT) After 5.5% Gain -- GF Value $38.24 vs Price $59.30 - GuruFocus
VCYT Maintained by Morgan Stanley -- Price Target Raised to $47. - GuruFocus
Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo
St. Pete woman seeks $10M in discrimination lawsuit against employer - Business Observer
Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside - TradingView
Jefferies Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative? - simplywall.st
Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group build - Ad-hoc-news.de
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy - Yahoo Finance
Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention? - simplywall.st
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - AOL.com
Veracyte Inc (VCYT) Stock Down 3.2% but Still Overvalued -- GF S - GuruFocus
Veracyte (VCYT) Edges Higher, Approaches Key Resistance Amid Steady TradingALMA Signal - dars.gov.et
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile - ChartMill
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. - Yahoo Finance
Veracyte Inc (VCYT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Veracyte Stock Surges 117% in a Year: What's Driving the Rally? - TradingView
VCYT Maintained by Guggenheim -- Price Target Raised to $65 - GuruFocus
Veracyte Price Target Raised to $65.00/Share From $45.00 by Guggenheim - Moomoo
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value Benchmark - marketscreener.com
Veracyte (VCYT) Enters Multiple Russell Indexes Is Its Small-Cap Profile Quietly Changing? - simplywall.st
Price to book forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value-Defensive Index - marketscreener.com
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Enterprise value to EBIT forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000 Value Benchmark - marketscreener.com
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):